Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN XL versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN XL versus TAO.
BIAXIN XL vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
500 mg orally once daily for 7 to 14 days
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic